P3‐296: BACE1 is not the rate‐limiting enzyme in Aβ production in the brains of APPswe transgenic mice: Pharmacological characterization of BACE1 using novel brain penetrant inhibitors.
David Riddell(Eli Lilly (United States)), Peter H. Reinhart(University of Massachusetts Amherst), Cathleen Gonzales, Stephen J. Moss(Tufts University), Warren D. Hirst(Pfizer (United States)), Raquel Revilla-Sanchez(Tufts University), Kai-Heng Fang(Princeton University), Michael S. Malamas(Pearl River Community College), Kristin Albinson(Princeton University), Iwan Gunawan(Pearl River Community College), Erik Wagner(Princeton University), James Turner(Unitec Institute of Technology), J. Erdel(Princeton University), Dongzi Yu(Princeton University), Jonathan Bard, Kevin Atchison(Merck & Co., Inc., Rahway, NJ, USA (United States)), Philip G. Haydon(Tufts University), Jaeuk Kim(Princeton University), Kazufumi Takano(Tufts University), Helen K. Warwick(Princeton University), Natasha Warren(Tufts University), A. J. ROBICHAUD(Princeton University), E. Wang(Princeton University), Suzan Aschmies(Princeton University), Menelas N. Pangalos(AstraZeneca (United Kingdom))
Cited by 1
Related Papers
Antibodies to the GABAB receptor in limbic encephalitis with seizures: case series and characterisation of the antigen
|The Lancet Neurology|2009|912
ApoE Promotes the Proteolytic Degradation of Aβ
|Neuron|2008|869
Application of the Bicyclo[1.1.1]pentane Motif as a Nonclassical Phenyl Ring Bioisostere in the Design of a Potent and Orally Active γ-Secretase Inhibitor
|Journal of Medicinal Chemistry|2012|460
Tau molecular diversity contributes to clinical heterogeneity in Alzheimer’s disease
|Nature Medicine|2020|445
Impact of Apolipoprotein E (ApoE) Polymorphism on Brain ApoE Levels
|Journal of Neuroscience|2008|351